• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
PublishDashboard
    Quantisnow Logo

    © 2025 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI employees
    Legal
    Terms of usePrivacy policyCookie policy
    Subscribe to $TMCI

    Treace Medical Concepts Inc.

    Subscribe to $TMCI
    $TMCI
    Medical/Dental Instruments
    Health Care

    Treace Medical Concepts, Inc., an orthopedic medical device company, engages in the design, manufacture, and marketing of device and/or biologic solutions for foot and ankle surgeons in the United States. It offers Lapiplasty procedure that allows podiatric surgeons to treat all three dimensions of the bunion, providing patients with a cosmetic and medical improvement. The company also provides Lapiplasty Mini-Incision precision system. In addition, it offers products to address ancillary surgical procedures, including akin osteotomies, weil osteotomies, intercuneiform stabilization, lesser tarsometatarsal joint fusions, and autograft bone harvesting, as well as for MTP fusion. Treace Medical Concepts, Inc. was incorporated in 2014 and is headquartered in Ponte Vedra Beach, Florida.

    IPO Year: 2021

    Exchange: NASDAQ

    Website: treace.com

    Recent Analyst Ratings for Treace Medical Concepts Inc.

    DatePrice TargetRatingAnalyst
    2/4/2025$16.00Neutral → Buy
    BTIG Research
    12/31/2024$14.50Buy
    Lake Street
    12/17/2024$8.00Neutral
    Analyst
    5/16/2024$16.00 → $6.50Buy → Neutral
    UBS
    5/8/2024$15.00 → $5.50Overweight → Equal-Weight
    Morgan Stanley
    5/8/2024$17.00 → $7.00Buy → Hold
    Truist
    5/8/2024$15.00 → $6.00Buy → Hold
    Stifel
    5/8/2024$15.00 → $8.00Overweight → Neutral
    JP Morgan
    5/8/2024Buy → Neutral
    BTIG Research
    9/29/2023$24.00Buy
    UBS
    See more ratings

    Treace Medical Concepts Inc. Press Releases

    Fastest customizable press release news feed in the world

    See more
    • Treace Medical Concepts Reports First Quarter 2025 Financial Results

      PONTE VEDRA, Fla., May 08, 2025 (GLOBE NEWSWIRE) -- Treace Medical Concepts, Inc. ("Treace" or the "Company") (NASDAQ:TMCI), a medical technology company driving a fundamental shift in the surgical treatment of bunions and related midfoot deformities through its flagship Lapiplasty® and Adductoplasty® Procedures, today reported financial results for the first quarter ended March 31, 2025. Recent Highlights Generated revenue of $52.6 million in first quarter 2025 representing growth of 3% over the same period in 2024.Improved first quarter 2025 net loss by 15% to $(15.9) million compared to $(18.7) million in the same period in 2024. Improved adjusted EBITDA by 53% to $(3.8) million in th

      5/8/25 4:05:00 PM ET
      $TMCI
      Medical/Dental Instruments
      Health Care
    • Treace to Report First Quarter 2025 Financial Results on May 8, 2025

      PONTE VEDRA, Fla., April 24, 2025 (GLOBE NEWSWIRE) -- Treace Medical Concepts, Inc. ("Treace" or the "Company") (NASDAQ:TMCI), a medical technology company driving a fundamental shift in the surgical treatment of bunions and related midfoot deformities through its flagship Lapiplasty® and Adductoplasty® Procedures, today announced that it will release financial results for the first quarter 2025 after the close of trading on Thursday, May 8, 2025. Company management will host a conference call to discuss financial results beginning at 4:30 pm ET. Investors interested in listening to the conference call may do so by registering. Once registered, participants will receive dial-in numbers an

      4/24/25 4:05:00 PM ET
      $TMCI
      Medical/Dental Instruments
      Health Care
    • Treace Announces Upcoming Board Chair Transition

      PONTE VEDRA, Fla., April 07, 2025 (GLOBE NEWSWIRE) -- Treace Medical Concepts, Inc. ("Treace" or the "Company") (NASDAQ:TMCI), a medical technology company driving a fundamental shift in the surgical treatment of bunions and related midfoot deformities through its flagship Lapiplasty® and Adductoplasty® Procedures, today announced that its Board of Directors has appointed John. T. Treace, Chief Executive Officer and Founder of Treace, as the Chairman of the Board to be effective immediately following the 2025 annual meeting of stockholders. Mr. John. T. Treace will succeed James T. Treace, who notified the Board that he will retire from the Board when his current term as a director ends at

      4/7/25 8:00:00 AM ET
      $TMCI
      Medical/Dental Instruments
      Health Care
    • Treace Announces Clinical Study Data Demonstrating Positive Lapiplasty® and Adductoplasty® Outcomes at the 2025 ACFAS Annual Scientific Conference

      PONTE VEDRA, Fla., March 28, 2025 (GLOBE NEWSWIRE) -- Treace Medical Concepts, Inc. ("Treace" or the "Company") (NASDAQ:TMCI), a medical technology company driving a fundamental shift in the surgical treatment of bunions and related midfoot deformities through its flagship Lapiplasty® and Adductoplasty® Procedures, today announced the presentation of updated interim data for the ALIGN3D™ and Mini3D™ Lapiplasty® clinical studies, as well as the first presentation of the MTA3D™ Adductoplasty® clinical study, at the 2025 American College of Foot and Ankle Surgeons (ACFAS) Annual Meeting in Phoenix, Arizona. "We are excited to feature our growing body of clinical data to surgeons attending

      3/28/25 2:00:00 PM ET
      $TMCI
      Medical/Dental Instruments
      Health Care
    • Treace Highlights New Innovations at the 2025 ACFAS Annual Scientific Conference

      PONTE VEDRA, Fla., March 25, 2025 (GLOBE NEWSWIRE) -- Treace Medical Concepts, Inc. ("Treace" or the "Company") (NASDAQ:TMCI), a medical technology company driving a fundamental shift in the surgical treatment of bunions and related midfoot deformities through its flagship Lapiplasty® and Adductoplasty® Procedures, today announced new technology innovations featured at the 2025 American College of Foot and Ankle Surgeons ("ACFAS") Annual Scientific Conference in Phoenix, Arizona from March 27-30, 2025. "We are excited to have another strong presence at ACFAS, highlighting our commitment to surgical podiatry and advancing our company's focused mission to improve surgical outcomes for bunio

      3/25/25 4:15:00 PM ET
      $TMCI
      Medical/Dental Instruments
      Health Care
    • Treace Medical Concepts Reports Fourth Quarter and Full-Year 2024 Financial Results

      PONTE VEDRA, Fla., Feb. 27, 2025 (GLOBE NEWSWIRE) -- Treace Medical Concepts, Inc. ("Treace" or the "Company") (NASDAQ:TMCI), a medical technology company driving a fundamental shift in the surgical treatment of bunions and related midfoot deformities through its flagship Lapiplasty® and Adductoplasty® Procedures, today reported financial results for the fourth quarter and full year ended December 31, 2024. Recent Highlights Revenue of $68.7 million in fourth quarter 2024 increased 10% over same period in 2023. Revenue of $209.4 million for full-year 2024 increased 12% compared to the prior year.Fourth quarter 2024 net loss was ($0.5) million compared to ($6.3) million for same period in

      2/27/25 4:05:00 PM ET
      $TMCI
      Medical/Dental Instruments
      Health Care
    • Treace to Report Fourth Quarter and Full-Year 2024 Financial Results on February 27, 2025

      PONTE VEDRA, Fla., Feb. 06, 2025 (GLOBE NEWSWIRE) -- Treace Medical Concepts, Inc. ("Treace" or the "Company") (NASDAQ:TMCI), a medical technology company driving a fundamental shift in the surgical treatment of bunions and related midfoot deformities through its flagship Lapiplasty® and Adductoplasty® Procedures, today announced that it will release financial results for the fourth quarter and full year of 2024 after the close of trading on Thursday, February 27, 2025. Company management will host a conference call to discuss financial results beginning at 4:30 pm ET. Investors interested in listening to the conference call may do so by registering. Once registered, participants will rec

      2/6/25 4:15:00 PM ET
      $TMCI
      Medical/Dental Instruments
      Health Care
    • Treace Announces First Surgical Cases Utilizing the SpeedAkin™ Anatomic Compression Implant

      PONTE VEDRA, Fla., Jan. 30, 2025 (GLOBE NEWSWIRE) -- Treace Medical Concepts, Inc. ("Treace" or the "Company") (NASDAQ:TMCI), a medical technology company driving a fundamental shift in the surgical treatment of bunions and related midfoot deformities through its flagship Lapiplasty® and Adductoplasty® Procedures, today announced the successful completion of the first cases utilizing its SpeedAkin™ Anatomic Compression Implant. The SpeedAkin™ implant broadens the procedural versatility of Treace's flagship SpeedPlate™ fixation platform, which is advancing a new standard in bone fusion fixation. Akin osteotomies are corrective straightening procedures of the great toe commonly performed in

      1/30/25 8:00:00 AM ET
      $TMCI
      Medical/Dental Instruments
      Health Care
    • Treace Announces Preliminary, Unaudited Fourth Quarter and Full-Year 2024 Revenue

      PONTE VEDRA, Fla., Jan. 13, 2025 (GLOBE NEWSWIRE) -- Treace Medical Concepts, Inc. ("Treace" or the "Company") (NASDAQ:TMCI), a medical technology company driving a fundamental shift in the surgical treatment of bunions and related midfoot deformities through its flagship Lapiplasty® and Adductoplasty® Procedures, today announced its preliminary, unaudited fourth quarter and full-year 2024 results. Highlights: Preliminary revenue of $68.4 million to $68.8 million in the fourth quarter of 2024, an approximate 10% increase at the midpoint over the same period in 2023.Preliminary revenue of $209.0 million to $209.4 million for the full-year 2024, an approximate 12% increase at the midpoint

      1/13/25 8:00:00 AM ET
      $TMCI
      Medical/Dental Instruments
      Health Care
    • Treace to Present at 43rd Annual J.P. Morgan Healthcare Conference

      PONTE VEDRA, Fla., Jan. 02, 2025 (GLOBE NEWSWIRE) -- Treace Medical Concepts, Inc. ("Treace" or the "Company") (NASDAQ:TMCI), a medical technology company driving a fundamental shift in the surgical treatment of bunions and related midfoot deformities through its flagship Lapiplasty® and Adductoplasty® Procedures, today announced that John T. Treace, Chief Executive Officer, will present at the 43rd Annual J.P. Morgan Healthcare Conference on Tuesday, January 14, 2025, beginning at approximately 9:00 am PT. A live webcast and replay of the fireside chat will be available on the Company's investors relations website at https://investors.treace.com/. Internet Posting of Information Treace

      1/2/25 4:15:00 PM ET
      $TMCI
      Medical/Dental Instruments
      Health Care

    Treace Medical Concepts Inc. SEC Filings

    See more
    • Treace Medical Concepts Inc. filed SEC Form 8-K: Submission of Matters to a Vote of Security Holders, Financial Statements and Exhibits

      8-K - TREACE MEDICAL CONCEPTS, INC. (0001630627) (Filer)

      5/21/25 4:30:09 PM ET
      $TMCI
      Medical/Dental Instruments
      Health Care
    • SEC Form SCHEDULE 13G filed by Treace Medical Concepts Inc.

      SCHEDULE 13G - TREACE MEDICAL CONCEPTS, INC. (0001630627) (Subject)

      5/15/25 4:30:03 PM ET
      $TMCI
      Medical/Dental Instruments
      Health Care
    • Amendment: SEC Form SCHEDULE 13G/A filed by Treace Medical Concepts Inc.

      SCHEDULE 13G/A - TREACE MEDICAL CONCEPTS, INC. (0001630627) (Subject)

      5/15/25 3:19:09 PM ET
      $TMCI
      Medical/Dental Instruments
      Health Care
    • SEC Form S-8 filed by Treace Medical Concepts Inc.

      S-8 - TREACE MEDICAL CONCEPTS, INC. (0001630627) (Filer)

      5/9/25 8:43:56 AM ET
      $TMCI
      Medical/Dental Instruments
      Health Care
    • SEC Form 10-Q filed by Treace Medical Concepts Inc.

      10-Q - TREACE MEDICAL CONCEPTS, INC. (0001630627) (Filer)

      5/8/25 4:10:24 PM ET
      $TMCI
      Medical/Dental Instruments
      Health Care
    • Treace Medical Concepts Inc. filed SEC Form 8-K: Results of Operations and Financial Condition, Financial Statements and Exhibits

      8-K - TREACE MEDICAL CONCEPTS, INC. (0001630627) (Filer)

      5/8/25 4:05:29 PM ET
      $TMCI
      Medical/Dental Instruments
      Health Care
    • SEC Form DEF 14A filed by Treace Medical Concepts Inc.

      DEF 14A - TREACE MEDICAL CONCEPTS, INC. (0001630627) (Filer)

      4/7/25 8:10:27 AM ET
      $TMCI
      Medical/Dental Instruments
      Health Care
    • Treace Medical Concepts Inc. filed SEC Form 8-K: Leadership Update, Financial Statements and Exhibits

      8-K - TREACE MEDICAL CONCEPTS, INC. (0001630627) (Filer)

      4/7/25 8:05:07 AM ET
      $TMCI
      Medical/Dental Instruments
      Health Care
    • SEC Form DEFA14A filed by Treace Medical Concepts Inc.

      DEFA14A - TREACE MEDICAL CONCEPTS, INC. (0001630627) (Filer)

      4/7/25 8:05:03 AM ET
      $TMCI
      Medical/Dental Instruments
      Health Care
    • SEC Form 10-K filed by Treace Medical Concepts Inc.

      10-K - TREACE MEDICAL CONCEPTS, INC. (0001630627) (Filer)

      2/27/25 4:06:07 PM ET
      $TMCI
      Medical/Dental Instruments
      Health Care

    Treace Medical Concepts Inc. Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    See more
    • Director Jain Deepti was granted 23,917 shares, increasing direct ownership by 52% to 70,243 units (SEC Form 4)

      4 - TREACE MEDICAL CONCEPTS, INC. (0001630627) (Issuer)

      5/21/25 5:30:14 PM ET
      $TMCI
      Medical/Dental Instruments
      Health Care
    • Director Mott Richard W was granted 23,917 shares, increasing direct ownership by 2% to 1,096,861 units (SEC Form 4)

      4 - TREACE MEDICAL CONCEPTS, INC. (0001630627) (Issuer)

      5/21/25 5:30:05 PM ET
      $TMCI
      Medical/Dental Instruments
      Health Care
    • Director Hanna Betsy was granted 23,917 shares, increasing direct ownership by 112% to 45,243 units (SEC Form 4)

      4 - TREACE MEDICAL CONCEPTS, INC. (0001630627) (Issuer)

      5/21/25 5:30:07 PM ET
      $TMCI
      Medical/Dental Instruments
      Health Care
    • Director Hamilton Lawrence W was granted 23,917 shares, increasing direct ownership by 119% to 44,056 units (SEC Form 4)

      4 - TREACE MEDICAL CONCEPTS, INC. (0001630627) (Issuer)

      5/21/25 5:30:11 PM ET
      $TMCI
      Medical/Dental Instruments
      Health Care
    • Director Berry Lance A was granted 23,917 shares, increasing direct ownership by 116% to 44,593 units (SEC Form 4)

      4 - TREACE MEDICAL CONCEPTS, INC. (0001630627) (Issuer)

      5/21/25 5:30:13 PM ET
      $TMCI
      Medical/Dental Instruments
      Health Care
    • Director Kiernan Jane E was granted 23,917 shares, increasing direct ownership by 60% to 63,949 units (SEC Form 4)

      4 - TREACE MEDICAL CONCEPTS, INC. (0001630627) (Issuer)

      5/21/25 5:30:09 PM ET
      $TMCI
      Medical/Dental Instruments
      Health Care
    • Director Bakewell John K was granted 23,917 shares, increasing direct ownership by 16% to 174,056 units (SEC Form 4)

      4 - TREACE MEDICAL CONCEPTS, INC. (0001630627) (Issuer)

      5/21/25 5:30:04 PM ET
      $TMCI
      Medical/Dental Instruments
      Health Care
    • Chief Legl & Comp Off, CorpSec Elder Scot Michael was granted 7,775 shares and covered exercise/tax liability with 1,894 shares, increasing direct ownership by 1% to 576,664 units (SEC Form 4)

      4 - TREACE MEDICAL CONCEPTS, INC. (0001630627) (Issuer)

      5/12/25 5:30:05 PM ET
      $TMCI
      Medical/Dental Instruments
      Health Care
    • Chief Innovation Officer Scanlan Sean F. exercised 50,000 shares at a strike of $1.05 and sold $398,460 worth of shares (50,000 units at $7.97) (SEC Form 4)

      4 - TREACE MEDICAL CONCEPTS, INC. (0001630627) (Issuer)

      3/19/25 9:30:04 PM ET
      $TMCI
      Medical/Dental Instruments
      Health Care
    • SVP, Sales Berutti Aaron covered exercise/tax liability with 2,543 shares, decreasing direct ownership by 1% to 209,999 units (SEC Form 4)

      4 - TREACE MEDICAL CONCEPTS, INC. (0001630627) (Issuer)

      3/11/25 9:00:14 PM ET
      $TMCI
      Medical/Dental Instruments
      Health Care

    Treace Medical Concepts Inc. Leadership Updates

    Live Leadership Updates

    See more
    • Treace Appoints Guy Guglielmino as Chief Commercial Officer

      PONTE VEDRA, Fla., Dec. 02, 2024 (GLOBE NEWSWIRE) -- Treace Medical Concepts, Inc. ("Treace" or the "Company") (NASDAQ:TMCI), a medical technology company driving a fundamental shift in the surgical treatment of bunions and related midfoot deformities through its flagship Lapiplasty® and Adductoplasty® Procedures, today announced that Guy Guglielmino joined the Company as Chief Commercial Officer. In this new position, Mr. Guglielmino will lead Treace's commercial efforts and play a pivotal role in driving the Company's next phase of rapid innovation, strategic product commercialization, and growth. "I am thrilled to welcome Guy to the Treace team," said John T. Treace, CEO, Founder and B

      12/2/24 4:15:00 PM ET
      $TMCI
      Medical/Dental Instruments
      Health Care
    • Treace Medical Concepts Appoints Nathan Minnich as Senior Vice President, Marketing

      PONTE VEDRA, Fla., Aug. 21, 2023 (GLOBE NEWSWIRE) -- Treace Medical Concepts, Inc. ("Treace" or the "Company") (NASDAQ:TMCI), a medical technology company driving a fundamental shift in the surgical treatment of hallux valgus (commonly known as bunions) through its Lapiplasty® 3D Bunion Correction™ Procedure, today announced Nathan Minnich has been appointed Sr. Vice President, Marketing, effective immediately. In this new position, Mr. Minnich will lead all aspects of Treace's marketing efforts, with a focus on expanding the Company's physician outreach, patient awareness and market penetration efforts.  "I am delighted to welcome Nathan to the Treace team," said John T. Treace, CEO, Fou

      8/21/23 7:00:00 AM ET
      $TMCI
      Medical/Dental Instruments
      Health Care
    • Treace Appoints Julie Dewey as Chief Communications and Investor Relations Officer

      PONTE VEDRA, Fla., July 12, 2023 (GLOBE NEWSWIRE) -- Treace Medical Concepts, Inc. ("Treace" or the "Company") (NASDAQ:TMCI), a medical technology company driving a fundamental shift in the surgical treatment of hallux valgus (commonly known as bunions) through its Lapiplasty® 3D Bunion Correction™ Procedure, today announced that Julie Dewey will join the Company as Chief Communications and Investor Relations Officer, effective July 17, 2023. In this new position, Ms. Dewey will lead all aspects of Treace's corporate communications and investor relations engagement, with a focus on expanding the company's outreach with the investment community and broadening the Company's relationships wit

      7/12/23 4:15:00 PM ET
      $TMCI
      Medical/Dental Instruments
      Health Care
    • Treace Medical Concepts Appoints New Directors

      PONTE VEDRA, Fla., Sept. 27, 2022 (GLOBE NEWSWIRE) -- Treace Medical Concepts, Inc. ("Treace" or the "Company") (NASDAQ:TMCI), a medical technology company driving a fundamental shift in the surgical treatment of hallux valgus (commonly known as bunions), today announced the appointment of Lance E. Berry and Jane E. Kiernan to its board of directors, effective October 1, 2022. "With decades of combined experience leading medical device companies, Lance and Jane strengthen the expertise of our Company's board of directors," said James T. Treace, the Company's Chairman of the Board. "Our executive leadership and board look forward to their support and guidance through our next phase of grow

      9/27/22 4:15:00 PM ET
      $TMCI
      Medical/Dental Instruments
      Health Care
    • IMPULSE DYNAMICS APPOINTS FIVE NEW BOARD MEMBERS

      MARLTON, N.J., Nov. 11, 2021 (GLOBE NEWSWIRE) -- Impulse Dynamics N.V., a company dedicated to improving the lives of people with heart failure (HF), today announced the election of five new members to its Board of Directors at the most recent meeting of its shareholders.  "We are extremely pleased to have Jim Tobin, Joe Capper, Glenn Muir, John Bakewell, and Dan Scavila all joining our board of directors," said Prof. Shlomo Ben-Haim, Chairman of the Board and Founder of Impulse Dynamics.  "This is an illustrious group to be adding to the board, and I am extremely pleased to be welcoming and working with all of them as we rapidly advance our goals for the company, for CCM therapy, and mo

      11/11/21 7:26:31 PM ET
      $BEAT
      $GMED
      $GTHX
      $HOLX
      Medical/Dental Instruments
      Health Care
      Biotechnology: Pharmaceutical Preparations
      Medical Electronics
    • Treace Medical Concepts Appoints New Directors

      PONTE VEDRA, Fla., Oct. 04, 2021 (GLOBE NEWSWIRE) -- Treace Medical Concepts, Inc. ("Treace" or the "Company") (NASDAQ:TMCI), a commercial-stage orthopaedic medical device company driving a paradigm shift in the surgical treatment of Hallux Valgus (commonly known as bunions), today announced the appointment of Betsy Hanna and Deepti Jain to its Board of Directors effective October 1, 2021. "With decades of combined experience in healthcare leadership, Ms. Hanna and Ms. Jain strengthen the expertise of our Company's Board of Directors," said James T. Treace, the Company's Chairman of the Board. "Our executive leadership and board are pleased to add two individuals with their stellar reputa

      10/4/21 8:00:00 AM ET
      $ANTM
      $TCMD
      $TMCI
      Medical Specialities
      Health Care
      Medical/Dental Instruments

    Treace Medical Concepts Inc. Insider Purchases

    Insider purchases reveal critical bullish sentiment about the company from key stakeholders. See them live in this feed.

    See more
    • Chief Executive Officer Treace John T. bought $524,064 worth of shares (60,000 units at $8.73), increasing direct ownership by 0.89% to 6,796,190 units (SEC Form 4)

      4 - TREACE MEDICAL CONCEPTS, INC. (0001630627) (Issuer)

      3/4/25 6:30:03 PM ET
      $TMCI
      Medical/Dental Instruments
      Health Care
    • Chief Executive Officer Treace John T. bought $265,630 worth of shares (50,000 units at $5.31), increasing direct ownership by 0.77% to 6,523,095 units (SEC Form 4)

      4 - TREACE MEDICAL CONCEPTS, INC. (0001630627) (Issuer)

      9/17/24 5:17:19 PM ET
      $TMCI
      Medical/Dental Instruments
      Health Care
    • Director Treace James T bought $501,035 worth of shares (84,000 units at $5.96), increasing direct ownership by 7% to 1,223,441 units (SEC Form 4)

      4 - TREACE MEDICAL CONCEPTS, INC. (0001630627) (Issuer)

      8/19/24 9:00:08 AM ET
      $TMCI
      Medical/Dental Instruments
      Health Care
    • Chief Executive Officer Treace John T. bought $510,314 worth of shares (85,000 units at $6.00), increasing direct ownership by 1% to 6,473,095 units (SEC Form 4)

      4 - TREACE MEDICAL CONCEPTS, INC. (0001630627) (Issuer)

      8/15/24 5:30:02 PM ET
      $TMCI
      Medical/Dental Instruments
      Health Care
    • Chief Executive Officer Treace John T. bought $264,600 worth of shares (45,000 units at $5.88), increasing direct ownership by 0.71% to 6,388,095 units (SEC Form 4)

      4 - TREACE MEDICAL CONCEPTS, INC. (0001630627) (Issuer)

      6/11/24 5:30:03 PM ET
      $TMCI
      Medical/Dental Instruments
      Health Care
    • Treace James T bought $151,328 worth of shares (25,000 units at $6.05), increasing direct ownership by 2% to 1,139,441 units (SEC Form 4)

      4 - TREACE MEDICAL CONCEPTS, INC. (0001630627) (Issuer)

      6/3/24 4:30:08 PM ET
      $TMCI
      Medical/Dental Instruments
      Health Care
    • Treace James T bought $130,062 worth of shares (25,000 units at $5.20), increasing direct ownership by 2% to 1,114,441 units (SEC Form 4)

      4 - TREACE MEDICAL CONCEPTS, INC. (0001630627) (Issuer)

      5/30/24 5:04:07 PM ET
      $TMCI
      Medical/Dental Instruments
      Health Care
    • Treace James T bought $253,475 worth of shares (50,000 units at $5.07), increasing direct ownership by 5% to 1,089,441 units (SEC Form 4)

      4 - TREACE MEDICAL CONCEPTS, INC. (0001630627) (Issuer)

      5/29/24 4:33:18 PM ET
      $TMCI
      Medical/Dental Instruments
      Health Care
    • Mott Richard W bought $93,501 worth of shares (18,000 units at $5.19), increasing direct ownership by 2% to 1,072,944 units (SEC Form 4)

      4 - TREACE MEDICAL CONCEPTS, INC. (0001630627) (Issuer)

      5/28/24 4:30:14 PM ET
      $TMCI
      Medical/Dental Instruments
      Health Care
    • Mott Richard W bought $60,425 worth of shares (12,100 units at $4.99), increasing direct ownership by 1% to 1,054,944 units (SEC Form 4)

      4 - TREACE MEDICAL CONCEPTS, INC. (0001630627) (Issuer)

      5/23/24 4:30:28 PM ET
      $TMCI
      Medical/Dental Instruments
      Health Care

    Treace Medical Concepts Inc. Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    See more
    • Treace Medical Concepts upgraded by BTIG Research with a new price target

      BTIG Research upgraded Treace Medical Concepts from Neutral to Buy and set a new price target of $16.00

      2/4/25 7:10:07 AM ET
      $TMCI
      Medical/Dental Instruments
      Health Care
    • Lake Street initiated coverage on Treace Medical Concepts with a new price target

      Lake Street initiated coverage of Treace Medical Concepts with a rating of Buy and set a new price target of $14.50

      12/31/24 7:48:21 AM ET
      $TMCI
      Medical/Dental Instruments
      Health Care
    • Analyst resumed coverage on Treace Medical Concepts with a new price target

      Analyst resumed coverage of Treace Medical Concepts with a rating of Neutral and set a new price target of $8.00

      12/17/24 8:22:27 AM ET
      $TMCI
      Medical/Dental Instruments
      Health Care
    • Treace Medical Concepts downgraded by UBS with a new price target

      UBS downgraded Treace Medical Concepts from Buy to Neutral and set a new price target of $6.50 from $16.00 previously

      5/16/24 7:37:21 AM ET
      $TMCI
      Medical/Dental Instruments
      Health Care
    • Treace Medical Concepts downgraded by Morgan Stanley with a new price target

      Morgan Stanley downgraded Treace Medical Concepts from Overweight to Equal-Weight and set a new price target of $5.50 from $15.00 previously

      5/8/24 9:34:25 AM ET
      $TMCI
      Medical/Dental Instruments
      Health Care
    • Treace Medical Concepts downgraded by Truist with a new price target

      Truist downgraded Treace Medical Concepts from Buy to Hold and set a new price target of $7.00 from $17.00 previously

      5/8/24 7:31:19 AM ET
      $TMCI
      Medical/Dental Instruments
      Health Care
    • Treace Medical Concepts downgraded by Stifel with a new price target

      Stifel downgraded Treace Medical Concepts from Buy to Hold and set a new price target of $6.00 from $15.00 previously

      5/8/24 6:40:53 AM ET
      $TMCI
      Medical/Dental Instruments
      Health Care
    • Treace Medical Concepts downgraded by JP Morgan with a new price target

      JP Morgan downgraded Treace Medical Concepts from Overweight to Neutral and set a new price target of $8.00 from $15.00 previously

      5/8/24 6:36:17 AM ET
      $TMCI
      Medical/Dental Instruments
      Health Care
    • Treace Medical Concepts downgraded by BTIG Research

      BTIG Research downgraded Treace Medical Concepts from Buy to Neutral

      5/8/24 6:35:41 AM ET
      $TMCI
      Medical/Dental Instruments
      Health Care
    • UBS initiated coverage on Treace Medical Concepts with a new price target

      UBS initiated coverage of Treace Medical Concepts with a rating of Buy and set a new price target of $24.00

      9/29/23 7:46:59 AM ET
      $TMCI
      Medical/Dental Instruments
      Health Care

    Treace Medical Concepts Inc. Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    See more
    • SEC Form SC 13G filed by Treace Medical Concepts Inc.

      SC 13G - TREACE MEDICAL CONCEPTS, INC. (0001630627) (Subject)

      11/14/24 3:38:23 PM ET
      $TMCI
      Medical/Dental Instruments
      Health Care
    • Amendment: SEC Form SC 13G/A filed by Treace Medical Concepts Inc.

      SC 13G/A - TREACE MEDICAL CONCEPTS, INC. (0001630627) (Subject)

      11/12/24 6:01:03 PM ET
      $TMCI
      Medical/Dental Instruments
      Health Care
    • SEC Form SC 13G filed by Treace Medical Concepts Inc.

      SC 13G - TREACE MEDICAL CONCEPTS, INC. (0001630627) (Subject)

      11/8/24 3:44:13 PM ET
      $TMCI
      Medical/Dental Instruments
      Health Care
    • Amendment: SEC Form SC 13G/A filed by Treace Medical Concepts Inc.

      SC 13G/A - TREACE MEDICAL CONCEPTS, INC. (0001630627) (Subject)

      11/7/24 5:00:02 PM ET
      $TMCI
      Medical/Dental Instruments
      Health Care
    • Amendment: SEC Form SC 13G/A filed by Treace Medical Concepts Inc.

      SC 13G/A - TREACE MEDICAL CONCEPTS, INC. (0001630627) (Subject)

      11/4/24 1:58:47 PM ET
      $TMCI
      Medical/Dental Instruments
      Health Care
    • SEC Form SC 13G/A filed by Treace Medical Concepts Inc. (Amendment)

      SC 13G/A - TREACE MEDICAL CONCEPTS, INC. (0001630627) (Subject)

      2/14/24 3:12:19 PM ET
      $TMCI
      Medical/Dental Instruments
      Health Care
    • SEC Form SC 13G/A filed by Treace Medical Concepts Inc. (Amendment)

      SC 13G/A - TREACE MEDICAL CONCEPTS, INC. (0001630627) (Subject)

      2/13/24 5:15:57 PM ET
      $TMCI
      Medical/Dental Instruments
      Health Care
    • SEC Form SC 13G/A filed by Treace Medical Concepts Inc. (Amendment)

      SC 13G/A - TREACE MEDICAL CONCEPTS, INC. (0001630627) (Subject)

      2/9/24 5:00:09 PM ET
      $TMCI
      Medical/Dental Instruments
      Health Care
    • SEC Form SC 13G filed by Treace Medical Concepts Inc.

      SC 13G - TREACE MEDICAL CONCEPTS, INC. (0001630627) (Subject)

      1/29/24 5:25:53 PM ET
      $TMCI
      Medical/Dental Instruments
      Health Care
    • SEC Form SC 13G/A filed by Treace Medical Concepts Inc. (Amendment)

      SC 13G/A - TREACE MEDICAL CONCEPTS, INC. (0001630627) (Subject)

      2/13/23 4:07:04 PM ET
      $TMCI
      Medical/Dental Instruments
      Health Care

    Treace Medical Concepts Inc. Financials

    Live finance-specific insights

    See more
    • Treace Medical Concepts Reports First Quarter 2025 Financial Results

      PONTE VEDRA, Fla., May 08, 2025 (GLOBE NEWSWIRE) -- Treace Medical Concepts, Inc. ("Treace" or the "Company") (NASDAQ:TMCI), a medical technology company driving a fundamental shift in the surgical treatment of bunions and related midfoot deformities through its flagship Lapiplasty® and Adductoplasty® Procedures, today reported financial results for the first quarter ended March 31, 2025. Recent Highlights Generated revenue of $52.6 million in first quarter 2025 representing growth of 3% over the same period in 2024.Improved first quarter 2025 net loss by 15% to $(15.9) million compared to $(18.7) million in the same period in 2024. Improved adjusted EBITDA by 53% to $(3.8) million in th

      5/8/25 4:05:00 PM ET
      $TMCI
      Medical/Dental Instruments
      Health Care
    • Treace to Report First Quarter 2025 Financial Results on May 8, 2025

      PONTE VEDRA, Fla., April 24, 2025 (GLOBE NEWSWIRE) -- Treace Medical Concepts, Inc. ("Treace" or the "Company") (NASDAQ:TMCI), a medical technology company driving a fundamental shift in the surgical treatment of bunions and related midfoot deformities through its flagship Lapiplasty® and Adductoplasty® Procedures, today announced that it will release financial results for the first quarter 2025 after the close of trading on Thursday, May 8, 2025. Company management will host a conference call to discuss financial results beginning at 4:30 pm ET. Investors interested in listening to the conference call may do so by registering. Once registered, participants will receive dial-in numbers an

      4/24/25 4:05:00 PM ET
      $TMCI
      Medical/Dental Instruments
      Health Care
    • Treace to Report Fourth Quarter and Full-Year 2024 Financial Results on February 27, 2025

      PONTE VEDRA, Fla., Feb. 06, 2025 (GLOBE NEWSWIRE) -- Treace Medical Concepts, Inc. ("Treace" or the "Company") (NASDAQ:TMCI), a medical technology company driving a fundamental shift in the surgical treatment of bunions and related midfoot deformities through its flagship Lapiplasty® and Adductoplasty® Procedures, today announced that it will release financial results for the fourth quarter and full year of 2024 after the close of trading on Thursday, February 27, 2025. Company management will host a conference call to discuss financial results beginning at 4:30 pm ET. Investors interested in listening to the conference call may do so by registering. Once registered, participants will rec

      2/6/25 4:15:00 PM ET
      $TMCI
      Medical/Dental Instruments
      Health Care
    • Treace Announces Preliminary, Unaudited Fourth Quarter and Full-Year 2024 Revenue

      PONTE VEDRA, Fla., Jan. 13, 2025 (GLOBE NEWSWIRE) -- Treace Medical Concepts, Inc. ("Treace" or the "Company") (NASDAQ:TMCI), a medical technology company driving a fundamental shift in the surgical treatment of bunions and related midfoot deformities through its flagship Lapiplasty® and Adductoplasty® Procedures, today announced its preliminary, unaudited fourth quarter and full-year 2024 results. Highlights: Preliminary revenue of $68.4 million to $68.8 million in the fourth quarter of 2024, an approximate 10% increase at the midpoint over the same period in 2023.Preliminary revenue of $209.0 million to $209.4 million for the full-year 2024, an approximate 12% increase at the midpoint

      1/13/25 8:00:00 AM ET
      $TMCI
      Medical/Dental Instruments
      Health Care
    • Treace to Report Third Quarter 2024 Financial Results on November 5, 2024

      PONTE VEDRA, Fla., Oct. 22, 2024 (GLOBE NEWSWIRE) -- Treace Medical Concepts, Inc. ("Treace" or the "Company") (NASDAQ:TMCI), a medical technology company driving a fundamental shift in the surgical treatment of bunions and related midfoot deformities through its flagship Lapiplasty® and Adductoplasty® Procedures, today announced that it will release financial results for the third quarter of 2024 after the close of trading on Tuesday, November 5, 2024. Company management will host a conference call to discuss financial results beginning at 4:30 pm ET. Investors interested in listening to the conference call may do so by registering. Once registered, participants will receive dial-in nu

      10/22/24 4:30:00 PM ET
      $TMCI
      Medical/Dental Instruments
      Health Care
    • Treace to Report Second Quarter 2024 Financial Results on August 6, 2024

      PONTE VEDRA, Fla., July 18, 2024 (GLOBE NEWSWIRE) -- Treace Medical Concepts, Inc. ("Treace" or the "Company") (NASDAQ:TMCI), a medical technology company driving a fundamental shift in the surgical treatment of bunions and related midfoot deformities through its flagship Lapiplasty® and Adductoplasty® Procedures, today announced that it will release financial results for the second quarter of 2024 after the close of trading on Tuesday, August 6, 2024. Company management will host a conference call to discuss financial results beginning at 4:30 pm ET. Investors interested in listening to the conference call may do so by registering. Once registered, participants will receive dial-in numbe

      7/18/24 4:30:00 PM ET
      $TMCI
      Medical/Dental Instruments
      Health Care
    • Treace to Report First Quarter 2024 Financial Results

      PONTE VEDRA, Fla., April 09, 2024 (GLOBE NEWSWIRE) -- Treace Medical Concepts, Inc. ("Treace" or the "Company") (NASDAQ:TMCI), a medical technology company driving a fundamental shift in the surgical treatment of bunions and related midfoot deformities through its flagship Lapiplasty® and Adductoplasty® Procedures, today announced that it will release financial results for the first quarter of 2024 after the close of trading on Tuesday, May 7, 2024. Company management will host a conference call to discuss financial results beginning at 4:30 pm ET. Investors interested in listening to the conference call may do so by registering. Once registered, participants will receive dial-in number

      4/9/24 7:00:00 AM ET
      $TMCI
      Medical/Dental Instruments
      Health Care
    • Treace to Report Fourth Quarter and Full-Year 2023 Financial Results

      PONTE VEDRA, Fla., Feb. 07, 2024 (GLOBE NEWSWIRE) -- Treace Medical Concepts, Inc. ("Treace" or the "Company") (NASDAQ:TMCI), a medical technology company driving a fundamental shift in the surgical treatment of bunions and related midfoot deformities through its flagship Lapiplasty® and Adductoplasty® Procedures, today announced that it will release financial results for the fourth quarter and full year of 2023 after the close of trading on Tuesday, February 27, 2024. Company management will host a conference call to discuss financial results beginning at 4:30 pm ET. Investors interested in listening to the conference call may do so by registering. Once registered, participants will rece

      2/7/24 4:05:00 PM ET
      $TMCI
      Medical/Dental Instruments
      Health Care
    • Treace Announces Preliminary, Unaudited Fourth Quarter and Full-Year 2023 Revenue

      PONTE VEDRA, Fla., Jan. 08, 2024 (GLOBE NEWSWIRE) -- Treace Medical Concepts, Inc. ("Treace" or the "Company") (NASDAQ:TMCI), a medical technology company driving a fundamental shift in the surgical treatment of bunions and related midfoot deformities through its flagship Lapiplasty® and Adductoplasty® Procedures, today announced its preliminary, unaudited fourth quarter and full-year 2023 revenue results. Highlights: Preliminary revenue of $61.8 million to $62.2 million in the fourth quarter of 2023, an approximate 25% increase at the midpoint over the same period in 2022. Preliminary revenue of $186.7 million to $187.1 million for the full-year 2023, an approximate increas

      1/8/24 7:00:00 AM ET
      $TMCI
      Medical/Dental Instruments
      Health Care
    • Treace to Report Third Quarter 2023 Financial Results

      PONTE VEDRA, Fla., Oct. 16, 2023 (GLOBE NEWSWIRE) -- Treace Medical Concepts, Inc. ("Treace") (NASDAQ:TMCI), a medical technology company driving a fundamental shift in the surgical treatment of hallux valgus (commonly known as bunions) through its Lapiplasty® 3D Bunion Correction® Procedure, today announced that it will release financial results for the third quarter of 2023 after the close of trading on Thursday, November 9, 2023. Company management will host a conference call to discuss financial results beginning at 4:30 pm ET. Investors interested in listening to the conference call may do so by registering. Once registered, participants will receive dial-in numbers and a unique pin

      10/16/23 7:00:00 AM ET
      $TMCI
      Medical/Dental Instruments
      Health Care